


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method of inhibiting replication of a human immunodeficiency virus, said method comprising:

contacting a nucleocapsid protein of the virus with a compound having the formula:



wherein

R¹⁴, R¹⁵ and R¹⁶ are members independently selected from H, NO₂, Sb(O)(OH)₂, OR¹⁷, SR¹⁷, CN, NR¹⁷R¹⁸, COR¹⁸, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl

wherein

R¹⁷ and R¹⁸ are members independently selected from H, OR¹⁹, C(O)R¹⁹, and NR¹⁹R²⁰

wherein

R¹⁹ and R²⁰ are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl,

with the proviso that at least one of R¹⁴, R¹⁵ and R¹⁶ is other than H.

2. (original) The method according to claim 1, wherein at least one of R¹⁴, R¹⁵ and R¹⁶ comprises a member selected from carboxylic acid, carboxylic acid ester, and carboxylic acid amide.

3-7. (cancelled)

8. (currently amended) The method of claim 7 1, wherein the human immunodeficiency ~~lentivirus~~ is an HIV-1, ~~an HIV-2, or an HTLV-1~~.

9. (currently amended) The method according to claim 1 ~~or claim 4~~, wherein the contacting step occurs *in vivo*.

10. (currently amended) The method according to claim 1 ~~or claim 4~~, wherein the method further comprises contacting the virus with an anti-viral agent different from the compounds set out in claim 1.

11. (original) The method of claim 10, wherein said anti-viral agent is a anti-retroviral agent that is a nucleotide analogue or a protease inhibitor.

12. (original) The method of claim 11, wherein said anti-retroviral agent is a nucleotide analogue.

13. (original) The method of claim 12, wherein the nucleotides analogue is selected from the group consisting of an AZT, a ddCTP or a DDI analogue.

14. (original) The method of claim 11, wherein the anti-retroviral agent is a protease inhibitor.

15. (currently amended) The method of claim 1 ~~or claim 4~~, wherein said compound is administered to a human as a pharmaceutical formulation.

16. (original) The method of claim 15, wherein said compound is administered intra-vaginally or intra-rectally to inhibit the transmission of the virus.

17. (cancelled)

18. (currently amended) A pharmaceutical formulation comprising a therapeutically effective unit dose of a compound set out in claim 1 ~~or claim 4~~.

19. (original) The pharmaceutical formulation of claim 18, further comprising a pharmaceutical excipient.